Physician profile
George Ajjan
NPI 1992709521
$1,937.49
in general payments reported to CMS, 2019-2025
25 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $39.30 · 2021: $443 · 2022: $322 · 2023: $449 · 2024: $70.40 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.90 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $487.77 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $313.77 | 2019-2022 | |
| Ascend Therapeutics US, LLC | $246.69 | 2021 | |
| Hologic Sales and Service, LLC | $164.59 | 2022-2025 | Fluent Fluid Management System, Acessa Provu System, Novasure |
| Myovant Sciences INC. | $124.95 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $80.15 | 2021-2025 | |
| Lupin INC. | $54.76 | 2019-2020 | |
| Amgen INC. | $43.53 | 2021-2022 | |
| Exeltis, USA INC. | $42.14 | 2025 | Slynd |
| Vertical Pharmaceuticals, LLC | $41.81 | 2019-2020 | |
| Scynexis, INC. | $38.45 | 2021-2022 | |
| Pfizer INC. | $33.48 | 2021-2023 | |
| Organon LLC | $33.15 | 2022-2025 | Nexplanon |
| Pacira Pharmaceuticals Incorporated | $30.13 | 2022-2023 | Exparel |
| Therapeuticsmd, INC. | $30.08 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $28.98 | 2019-2022 | |
| Avion Pharmaceuticals | $27.43 | 2023 | Balcoltra |
| Meditrina | $16.16 | 2023 | |
| Exact Sciences Corporation | $15.67 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $15.43 | 2023 | Gemtesa |
| Evofem Biosciences, INC. | $15.00 | 2022 | |
| Urovant Sciences INC | $13.97 | 2022 | |
| Merck Sharp & Dohme LLC | $13.89 | 2019 | |
| Medicem INC. | $13.22 | 2021 | |
| Allergan, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Ajjan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.